Bioorganic & Medicinal Chemistry Letters 2006-03-15

Novel inhibitors of hepatitis C NS3-NS4A serine protease derived from 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid.

Srikanth Venkatraman, F George Njoroge, Wanli Wu, Viyyoor Girijavallabhan, Andrew J Prongay, Nancy Butkiewicz, John Pichardo

文献索引：Bioorg. Med. Chem. Lett. 16 , 1628, (2006)

全文：HTML全文

摘要

Prolonged hepatitis C infection is the leading cause for cirrhosis of the liver and hepatocellular carcinoma. The etiological agent HCV virus codes a single polyprotein of approximately 3000 amino acids that is processed with the help of a serine protease NS3A to produce structural and non-structural proteins required for viral replication. Inhibition of NS3 protease can potentially be used to develop drugs for treatment of HCV infections. Herein, we report the development of a series of novel NS3 serine protease inhibitors derived from 2-aza-bicyclo[2.2.1]-heptane carboxylic acid with potential therapeutic use for treatment of HCV infections.